AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16918659
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg x kg(‐1) of ketamine after surgery (Group III)
Trial: 15479482
Drug: Bevacizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (5 mg/kg I.V. every 2 weeks)
Trial: 9302444
Drug: Testosterone cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate 200 mg intramuscularly every 2 weeks for 3 months
Trial: 8391304
Drug: Granisetron (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (40 micrograms kg−1) as a single prophylactic 5-min infusion
Trial: 8391304
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide (loading dose of 3 mg kg−1 followed by maintenance dose of 4 mg kg−1 infused over 8 h) plus dexamethasone (12 mg as a 30-min infusion)
Trial: 8391304
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide plus dexamethasone
Trial: 27312945
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (intramuscular testosterone undecanoate)
Trial: 15953008
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of asparaginase (ASP) and steroids during the postinduction intensification phase, with high-risk patients receiving thrice the steroid dose compared to standard-risk patients.
Trial: 15953008
Drug: Older patients
RxNorm normalized name: black alder pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older patients (≥10 years) receiving the same treatment.
Trial: 15953008
Drug: High-risk (HR)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk (HR) treatment group receiving the same treatment.
Trial: 12748666
Drug: Interferon-alpha (IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN) treatment for a median duration of 5 months (1-18 months) until a median of 1 month prior to transplantation.
Trial: 12748666
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IFN treatment).
Trial: 12748666
Drug: Interferon-alpha (IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN) treatment.
Trial: 9579718
Drug: roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 150 mg bd
Trial: 9579718
Drug: co-amoxiclav 625
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-amoxiclav 625 mg tds
Trial: 7644852
Drug: Buflomedil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buflomedil (400 mg in bolus)
Trial: 7644852
Drug: Naftidrofuryl (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (200 mg in bolus)
Trial: 2528004
Drug: TE‐031 (clarithromycin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TE‐031 (clarithromycin) at a daily dosage of 400 mg in 2 divided doses
Trial: 2528004
Drug: JM (josamycin)
RxNorm normalized name: JM
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JM (josamycin) at a daily dosage of 1,200 mg in 3 divided doses
Trial: 766340
Drug: Daily rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rifampicin plus ethambutol (ER7)
Trial: 766340
Drug: Twice-weekly rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly rifampicin plus ethambutol (ER2)
Trial: 766340
Drug: Once-weekly rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly rifampicin plus ethambutol (ER1)
Trial: 766340
Drug: Daily for
RxNorm normalized name: Men's Daily Formula Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 2 months and then once-weekly rifampicin plus ethambutol (ER7ER1)
Trial: 766340
Drug: Standard retreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard retreatment regimen of daily ethionamide plus pyrazinamide plus cycloserine (EtZC)
Trial: 25605528
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with standardized JCP extract for five months over the pollen season
Trial: 21816071
Drug: 3.0 g
RxNorm normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g n‐3 LC‐PUFA/d
Trial: 21816071
Drug: 3.2 g
RxNorm normalized name: OATMEAL 2.3 g in 113.2 g TOPICAL CREAM [EczeNil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 g γ‐linolenic acid/d
Trial: 21816071
Drug: 1.6 g
RxNorm normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 g n‐3 LC‐PUFA + 1.8 g γ‐linolenic acid/d
Trial: 21816071
Drug: 3.0 g
RxNorm normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g olive oil
Trial: 18473961
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cytarabine with or without etoposide or mitoxantrone
Trial: 18473961
Drug: Timed sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timed sequential chemotherapy regimens
Trial: 15267080
Drug: Nicotine (21-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (21-mg transdermal patch)
Trial: 9085324
Drug: Train-of-four (TOF)
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Train-of-four (TOF) dosing of vecuronium
Trial: 9085324
Drug: Standard clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard clinical assessment dosing of vecuronium
Trial: 27163498
Drug: Delayed-release gastroresistant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release gastroresistant formulation of ketoprofen under fed conditions
Trial: 27163498
Drug: Delayed-release gastroresistant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release gastroresistant formulation of ketoprofen under fasting conditions
Trial: 22781424
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) for patients with LBBB
Trial: 22781424
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) for patients without LBBB
Trial: 20159726
Drug: NPPV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPPV therapy
Trial: 18316137
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg/day
Trial: 12814146
Drug: Telithromycin 800
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telithromycin 800 mg once daily for 7-10 days
Trial: 12814146
Drug: Comparator antibacterials
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator antibacterials (amoxicillin 1000 mg three-times daily, clarithromycin 500 mg twice daily, trovafloxacin 200 mg once daily)
Trial: 8607489
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. and azithromycin 500 mg mane (for the first 3 days)
Trial: 8607489
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy with omeprazole 20 mg b.i.d. plus amoxicillin 1 g t.i.d.
Trial: 1898142
Drug: Magnesium therapy
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium therapy (178 mEq over the first 4 postoperative days)
Trial: 6359047
Drug: Vidarabine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vidarabine 15 mg/kg/d
Trial: 6359047
Drug: Vidarabine 30
RxNorm normalized name: vidarabine 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vidarabine 30 mg/kg/d
Trial: 31589553
Drug: Insulin Resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Resistance (IR) prevalence measurement
Trial: 29401328
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment under ACC/AHA guidelines
Trial: 16281429
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (IVIg)
Trial: 12002292
Drug: Gonadotropin‐releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin‐releasing hormone analogue (GnRHa) for 1 month
Trial: 12002292
Drug: Gonadotropin‐releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin‐releasing hormone analogue (GnRHa) for 3 months
Trial: 12002292
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 15 mg for 3 months
Trial: 9653613
Drug: Reduced-dose lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reduced-dose lispro before dinner (20% reduction) and increased NPH at bedtime (125% of usual dose)
Trial: 9653613
Drug: Usual-dose lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Usual-dose lispro plus usual-dose NPH before dinner
Trial: 9653613
Drug: Standard premeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard premeal human regular insulin and pre-bedtime NPH insulin (control)
Trial: 8593015
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg oral valaciclovir
Trial: 8593015
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg [14C]valaciclovir
Trial: 2569686
Drug: OKY-046 80
RxNorm normalized name: OKI-179
DrugBank: OKI-179 (DB17583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKY-046 80 mg (L group)
Trial: 2569686
Drug: OKY-046 400
RxNorm normalized name: OKI-179
DrugBank: OKI-179 (DB17583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKY-046 400 mg (H group)
Trial: 31171523
Drug: Ticagrelor plus
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor plus aspirin (large artery atherosclerosis)
Trial: 31171523
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (large artery atherosclerosis)
Trial: 28427362
Drug: Budesonide/formoterol maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol maintenance and reliever therapy (MRT)
Trial: 28427362
Drug: Higher, fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher, fixed-dose budesonide plus as-needed terbutaline
Trial: 7778957
Drug: Intravenous ceftizoxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftizoxime sodium (1 g every 12 hours) or ceftriaxone sodium (1 g every 24 hours) followed by oral cefixime (400 mg every 24 hours) after meeting criteria for switch.
Trial: 2181111
Drug: ELISA for
RxNorm normalized name: pseudopterogorgia elisabethae extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELISA for antibodies to B. gingivalis and T. denticola
Trial: 31934993
Drug: BCD-132 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCD-132 (100 to 1000 mg intravenous infusion)
Trial: 23704673
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus lifestyle (M+L)
Trial: 23704673
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (M+R, M, M+L)
Trial: 21585061
Drug: Pricking bleeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pricking bleeding therapy (applied to specific points on the thumb and auricular helix), once daily for 7 days.
Trial: 21585061
Drug: Ultrasonic atomizing
RxNorm normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasonic atomizing inhalation (UAI), once daily for 7 days for 15 minutes.
Trial: 21585061
Drug: Pricking bleeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pricking bleeding therapy
Trial: 21585061
Drug: Ultrasonic atomizing
RxNorm normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasonic atomizing inhalation (UAI)
Trial: 19532041
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (add-on treatment)
Trial: 19532041
Drug: Monotherapy antiepileptic
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy antiepileptic drugs (head-to-head trials)
Trial: 16904458
Drug: Topical alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical alprostadil cream 100 microg
Trial: 16904458
Drug: Topical alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical alprostadil cream 200 microg
Trial: 16904458
Drug: Topical alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical alprostadil cream 300 microg
Trial: 16904458
Drug: Topical alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical alprostadil cream (all doses)
Trial: 10619583
Drug: irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irbesartan (150 mg)
Trial: 2042654
Drug: Calcium citrate,
RxNorm normalized name: calcium citrate, calcium malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium citrate, 950 mg four times a day
Trial: 2042654
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide (2.4 g/d)
Trial: 31451360
Drug: Self-administered web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered web-based decision aid
Trial: 16130190
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg mycophenolate mofetil (MMF) twice daily
Trial: 6218098
Drug: Mezlocillin treatment
RxNorm normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mezlocillin treatment
Trial: 19232039
Drug: Nebulized formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized formoterol fumarate inhalation solution (Perforomist, FFIS 20g BID)
Trial: 19232039
Drug: Ipratropium and
RxNorm normalized name: Ipratropium and salbutamol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium and albuterol combined in a metered-dose inhaler (MDI) (Combiventy, IPR-ALB, QID)
Trial: 17925883
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system (MTS) applied on the hip for nine hours.
Trial: 17250775
Drug: Dexamphetamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamphetamine (10 mg)
Trial: 14667790
Drug: Piperacillin-tazobactam 13.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam 13.5 g divided Q6H
Trial: 11007053
Drug: Moderate renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate renal failure, hypercalcaemia, low Bence-Jones protein excretion
Trial: 28328759
Drug: Topical ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ropivacaine (1% ropivacaine)
Trial: 22014897
Drug: Omitting elective
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omitting elective nodal irradiation (ENI) during thoracic irradiation with concurrent chemo-radiotherapy
Trial: 15059505
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride (RLX) 60 mg/day for 12 months
Trial: 9638964
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg (after dose increase)
Trial: 9638964
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg (after dose increase)
Trial: 2726115
Drug: Vaginal prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal prostaglandin E2 (3 mg)
Trial: 25943662
Drug: IV with
RxNorm normalized name: AEROSOL POWDER, BREATH ACTIV WITH SENSOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV with oral glycerol (50% IV fluid, 50% oral fluid with added glycerol 1.5g/kg)
Trial: 25943662
Drug: IV (50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV (50% IV fluid, 50% oral fluid)
Trial: 25943662
Drug: oral glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral glycerol (oral fluid with added glycerol 1.5g/kg)
Trial: 25943662
Drug: oral (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral (oral fluid only)
Trial: 25943662
Drug: IV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and IV with oral glycerol
Trial: 25943662
Drug: IV with
RxNorm normalized name: AEROSOL POWDER, BREATH ACTIV WITH SENSOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV with oral glycerol
Trial: 22553403
Drug: PEG (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG (500 mL ingested within 2 hours starting 30 minutes after swallowing the capsule)
Trial: 22553403
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional preparation (control group A)
Trial: 10696419
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg quinine salt/kg bodyweight daily for 7 days
Trial: 10696419
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg quinine salt/kg bodyweight daily for 7 days
Trial: 10696419
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg quinine salt/kg bodyweight daily for 7 days
Trial: 2286000
Drug: Ceftriaxone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (3 or 4 g per day for 2 or 3 days)
Trial: 26059981
Drug: rLH 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rLH 150 IU/day administered at GnRH-ant administration
Trial: 26059981
Drug: rLH 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rLH 150 IU/day administered from the start of rFSH administration
Trial: 26059981
Drug: rLH 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rLH 75 IU/day administered at GnRH-ant administration
Trial: 26059981
Drug: rLH 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rLH 75 IU/day administered from the start of rFSH administration
Trial: 26059981
Drug: rLH 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rLH 150 IU/day administered at rFSH administration
Trial: 26059981
Drug: rLH 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rLH 75 IU/day administered at rFSH administration
Trial: 24618336
Drug: Doxorubicin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (75 mg/m² by intravenous bolus on day 1 or 72 h continuous intravenous infusion)
Trial: 24618336
Drug: Doxorubicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin plus ifosfamide (Doxorubicin 75 mg/m²; 25 mg/m² per day, days 1-3 plus ifosfamide 10 g/m² over 4 days with mesna and pegfilgrastim)
Trial: 22118808
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT) or Escitalopram
Trial: 17855198
Drug: Bilateral single-shot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral single-shot paravertebral blocks (BSS-PVB) with low-dose fentanyl and 3 mL bupivacaine 0.5% each (T1-7)
Trial: 17855198
Drug: High thoracic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High thoracic epidural analgesia (TEA) with bupivacaine 0.125% at 10 mL/hour
Trial: 8331334
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NTR and PTI
Trial: 31491384
Drug: Broad-spectrum antibiotics
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum antibiotics administered prior and subsequent to seasonal influenza vaccination
Trial: 31491384
Drug: Broad-spectrum antibiotics
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum antibiotics administered to subjects with low pre-existing antibody titers